
Mar 28, 2024, 03:11
Yüksel Ürün: US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer
Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared a post on X:
“US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer!”
View additional information.
Source: Yüksel Ürün/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 27, 2025, 12:18
Mar 27, 2025, 11:49
Mar 27, 2025, 11:07
Mar 27, 2025, 10:22